Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lunai Bioworks Inc. (LNAI : NSDQ)

• Company Description    Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company. Lunai Bioworks Inc., formerly known as RENOVARO INC, is based in LOS ANGELES. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $2.33 Daily Weekly Monthly 20 Day Moving Average: 54,207 shares Shares Outstanding: 4.53 (millions) Market Capitalization: $10.56 (millions) Beta: 0.37 52 Week High: $28.00 52 Week Low: $1.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -34.55% -35.03% 12 Week -11.74% -14.16% Year To Date -66.97% -69.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3400 Cottage Way Suite G2 #32562 - Sacramento,CA 95825 USA ph: 1-424-222-9301 fax: - ir@lunaibioworks.com http://www.lunaibioworks.com

• General Corporate Information    Officers David Weinstein - Chief Executive Officer Nathen Fuentes - Chief Financial Officer Douglas W. Calder - Director James A. McNulty - Director Mark Collins - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: 29350E302 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/21/26 Share - Related Items Shares Outstanding: 4.53 Most Recent Split Date: 5.00 (0.13:1) Beta: 0.37 Market Capitalization: $10.56 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/21/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -25.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - -1,243.45 ROA 06/30/26 - - 03/31/26 - -1,617.76 12/31/25 - -360.31 Current Ratio 06/30/26 - - 03/31/26 - 0.19 12/31/25 - 0.03 Quick Ratio 06/30/26 - - 03/31/26 - 0.19 12/31/25 - 0.03 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - -610,877.00 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - -2.14 12/31/25 - -4.48 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©